|
Don Husereau is Director of Health Technology Assessment Development at the Canadian Agency for Drugs and Technologies in Health (CADTH) Ottawa, Ontario, Canada. He received his Bachelor of Science in Pharmacy in 1993 at the University of Alberta and worked in community pharmacy practice until 1996. He completed his MSc in Pharmacy and Pharmaceutical Sciences (Biotechnology) in 2000, where he also served as a lecturer and course facilitator for graduate and undergraduate courses. Prior to working at CADTH, he worked as a consultant for both the International Atomic Energy Agency and Canadian International Development Agency. He joined CADTH (formerly CCOHTA) in January, 2001. At CADTH, he has overseen the development of several programs, including a rapid assessment service for policy-makers. In 2005, he led the completion of the 3rd edition of the CADTH Health Technology Assessment (HTA) Guidelines for the Economic Evaluation of Health Technologies:
Canada. These guidelines represented the first attempt to create a Canadian national health economic evaluation guideline that extended beyond pharmaceutical interventions. In his current role at CADTH, he leads the identification and assignment of policy research. In this role, he acts as a convenor for discussions among health care researchers, health program managers (policy-makers), assessors, manufacturers, clinicians, and communications specialists with the aim of meeting decision-maker needs through the optimal application of research.
Don Husereau has led and served on several national and international committees. He is currently the chair of the Health Technology Analysis Exchange, a network of Canadian Health Technology Assessors. He has also served as an advisor for the development of the US Agency for Healthcare Research and Quality Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) network.
Don Husereau has successfully fostered international HTA collaborations with both the National Institute for Health Research HTA program (UK) and DAHTA@DIMDI (Germany). Through his more recent involvement with ISPOR, he has contributed to Health Technology Assessment Advisory Council discussions. He is also an academic editor for the Public Library of Science ONE journal and a member of the Cochrane Hypertension Review Group. His interests include health economic evaluation and scientific epistemology.
It is an honour to be asked to contribute to the leadership of ISPOR, an organization with esteemed and enthusiastic membership motivated by mass collaboration. Through transparency, education, sharing and acting globally, ISPOR members are committed to applying their unique expertise to optimizing the care of patients worldwide. It is clear that continued excellent leadership is required to both achieve and go beyond ISPOR VISION 2010. I believe that ISPOR can continue to be a model social network and reach its goals by providing increased attention to several key areas:
Promoting health-focused research: ISPOR members represent a wide-ranging set of perspectives, spanning across key players and jurisdictions that are responsible health delivery. Members know that excellent health, rather than excellent health science is their ultimate goal. The shift of focus from health science to health requires continued promotion of methods of valuation of uncertainty, rational priority setting, and ideas sharing in Society meetings and communications.
Promoting health-focused judgement and decision-making: ISPOR has fostered growth in the area of judgement and decision-making through groups such as the "Health Technology Assessment In Evidence-Based Decisions Group" and "HTA in Reimbursement Economics Working Group". The complexity of health decisions requires ISPOR members to increase their use of reliable knowledge transfer and decision science methods to maximize health impact.
Promoting health beyond interventions: New service and delivery paradigms for health mean decision-makers must consider organizational, health human resources, environmental risk management and information technology issues more than they have in the past. By furthering its Good Research Practice Standards, ISPOR is in a position to lead future health research in these areas. I believe I could quite effectively contribute to the ISPOR Board of Directors and I look forward to your vote and working with you.
TOP
|
